NEW YORK (GenomeWeb News) – SIRS-Lab, a German molecular diagnostic developer, said today that it has begun insolvency proceedings and it is seeking an investor to commercialize its leading product, a test for the causative agent of sepsis.
German molecular diagnostics firm SIRS-Lab this week commenced a 1,000-patient clinical study in its home country to evaluate Vyoo, the company's PCR- and microarray-based molecular test for causative agents of sepsis. Results from the study will support an application for regulatory approval in Europe.
The initial focus of the partnership will be on using molecular diagnostics to test for severe fungal blood stream infections and to evaluate the clinical impact and pharmacoeconomics of such an approach.
In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.